Q-omics provides the consensus-scored RNA5SP132 profile across patient tissues and cancer cell-line models. RNA5SP132 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, RNA5SP132 is differentially expressed in 6, with the highest sampling consensus in KIRC. Additionally, RNA5SP132 RNA expression shows 9,285 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, KIRC, and TGCT as cancer lineages where RNA5SP132 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNA5SP132 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNA5SP132 survival associations across molecular data types. RNA5SP132 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNA5SP132 RNA expression–survival associations across cancer types. High RNA5SP132 expression shows unfavorable associations in DLBC, THCA, KICH, PCPG and SKCM, but favorable associations in MESO. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify MESO as the clearest survival context for RNA5SP132 RNA expression.
This table summarizes RNA5SP132 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RNA5SP132. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNA5SP132 shows lower tumor expression in KIRC, KIRP and THCA and higher tumor expression in LUAD, KICH and READ. The KIRC box plot shows higher RNA5SP132 RNA expression in normal versus tumor tissue (log2 FC = −0.207, t-test p = .007).
This table shows molecular features associated with RNA5SP132 in patient tissues and cancer cell lines. In patient samples, RNA5SP132 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
